Literature DB >> 16156322

Varying rates of Clostridium difficile-associated diarrhea at prevention epicenter hospitals.

SeJean Sohn1, Michael Climo, Daniel Diekema, Victoria Fraser, Loreen Herwaldt, Susan Marino, Gary Noskin, Trish Perl, Xiaoyan Song, Jerome Tokars, David Warren, Edward Wong, Deborah S Yokoe, Theresa Zembower, Kent A Sepkowitz.   

Abstract

BACKGROUND: Clostridium difficile-associated diarrhea (CDAD) causes substantial healthcare-associated morbidity. Unlike other common healthcare-associated pathogens, little comparative information is available about CDAD rates in hospitalized patients.
OBJECTIVES: To determine CDAD rates per 10,000 patient-days and per 1,000 hospital admissions at 7 geographically diverse tertiary-care centers from 2000 to 2003, and to survey participating centers on methods of CDAD surveillance and case definition.
METHODS: Each center provided specific information for the study period, including case numbers, patient-days, and hospital characteristics. Case definitions and laboratory diagnoses of healthcare-associated CDAD were determined by each institution. Within institutions, case definitions remained consistent during the study period.
RESULTS: Overall, mean annual case rates of CDAD were 12.1 per 10,000 patient-days (range, 3.1 to 25.1) and 7.4 per 1,000 hospital admissions (range, 3.1 to 13.1). No significant increases were observed in CDAD case rates during the 4-year interval, either at individual centers or in the Prevention Epicenter hospitals as a whole. Prevention Epicenter hospitals differed in their CDAD case definitions. Different case definitions used by the hospitals applied to a fixed data set resulted in a 30% difference in rates. No associations were identified between diagnostic test or case definition used and the relative rate of CDAD at a specific medical center.
CONCLUSIONS: Rates of CDAD vary widely at tertiary-care centers across the United States. No significant increases in case rates were identified. The varying clinical and laboratory approaches to diagnosis complicated comparisons between hospitals. To facilitate benchmarking and comparisons between institutions, we recommend development of a more standardized case definition.

Entities:  

Mesh:

Year:  2005        PMID: 16156322     DOI: 10.1086/502601

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  11 in total

1.  Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis.

Authors:  Charlie G Buffie; Irene Jarchum; Michele Equinda; Lauren Lipuma; Asia Gobourne; Agnes Viale; Carles Ubeda; Joao Xavier; Eric G Pamer
Journal:  Infect Immun       Date:  2011-10-17       Impact factor: 3.441

2.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

3.  Multicenter study of Clostridium difficile infection rates from 2000 to 2006.

Authors:  Erik R Dubberke; Anne M Butler; Deborah S Yokoe; Jeanmarie Mayer; Bala Hota; Julie E Mangino; Yosef M Khan; Kyle J Popovich; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2010-10       Impact factor: 3.254

Review 4.  Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.

Authors:  Orna Nitzan; Mazen Elias; Bibiana Chazan; Raul Raz; Walid Saliba
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

5.  Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward.

Authors:  A H Gifford; K B Kirkland
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-12       Impact factor: 3.267

6.  Risk Factors Associated With Recurrent Clostridium difficile Infection.

Authors:  Nikhita Dharbhamulla; Ahmed Abdelhady; Mona Domadia; Sanket Patel; John Gaughan; Satyajeet Roy
Journal:  J Clin Med Res       Date:  2018-12-03

Review 7.  Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread.

Authors:  Archie C A Clements; Ricardo J Soares Magalhães; Andrew J Tatem; David L Paterson; Thomas V Riley
Journal:  Lancet Infect Dis       Date:  2010-06       Impact factor: 25.071

8.  Incidence and Outcomes Associated With Clostridium difficile Infections: A Systematic Review and Meta-analysis.

Authors:  Alexandre R Marra; Eli N Perencevich; Richard E Nelson; Matthew Samore; Karim Khader; Hsiu-Yin Chiang; Margaret L Chorazy; Loreen A Herwaldt; Daniel J Diekema; Michelle F Kuxhausen; Amy Blevins; Melissa A Ward; Jennifer S McDanel; Rajeshwari Nair; Erin Balkenende; Marin L Schweizer
Journal:  JAMA Netw Open       Date:  2020-01-03

Review 9.  Toward a structural understanding of Clostridium difficile toxins A and B.

Authors:  Rory N Pruitt; D Borden Lacy
Journal:  Front Cell Infect Microbiol       Date:  2012-03-16       Impact factor: 5.293

10.  Global burden of Clostridium difficile infections: a systematic review and meta-analysis.

Authors:  Evelyn Balsells; Ting Shi; Callum Leese; Iona Lyell; John Burrows; Camilla Wiuff; Harry Campbell; Moe H Kyaw; Harish Nair
Journal:  J Glob Health       Date:  2019-06       Impact factor: 4.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.